Acerta Pharma, AstraZeneca deal

AstraZeneca completed its acquisition of a 55% stake in Acerta for $2.5 billion in cash. Acerta will also receive a $1.5 billion payment upon U.S. approval of acalabrutinib for any indication or the ...